Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
Unknown authors
Abstract
Bapineuzumab-1, Solanezumab-1, Solanezumab-2, and Gantenerumab. Data for the EMERGE and ENGAGE trials of Aducanumab were previously obtained from the only source available at the time, but cognitive data for these trials were subsequently updated on ClinicalTrials.gov and are shown here. Data from a publication available at the time of original publication were replaced with data from ClinicalTrials.gov for Verubecestat-2. 2 The updated results do not include data that are not currently publicly available (Lecanemab) or from trials that were not completed at the time of the original publication (Donanemab). Figure These results do not substantively change the primary results in the original publication: the meta-analyzed estimate of the effect of amyloid reduction on cognitive change as measured with the mini-mental state examination across 40 arms of 14 trials is small and consistent with the null.